title: Endometriosis: medical therapy.
abstract: The management of women with endometriosis is complex and necessitates individualization of patient care. The most commonly used medical therapies are danazol, GnRH agonists, medroxyprogesterone acetate and gestrinone. Studies to date have shown these drugs to have equal efficacy in terms of reduction in laparoscopic score and relief of symptoms. However, their side-effects make them unsuitable for long-term use. The addition of low dose hormone replacement therapy to GnRH agonist regimens may allow prolonged use but the current cost of these agents is high. Low dose oral contraceptive pills deserve further investigation. The role of medical treatment for women with endometriosis and infertility is controversial. There is no place for hormonal therapy in such women with stage I or II disease. When expectant management fails, gamete intrafallopian transfer offers excellent results. For those with stage III or IV disease, surgery is preferable with adjunctive medical therapy in selected cases. If pregnancy does not ensue, in vitro fertilization and embryo transfer are the next line of management, and results are optimized by prior medical therapy and aspiration of endometriomas. Major advances have been made in the medical management of endometriosis. However, current treatment strategies are ineffective in eliminating the disease in most women. New approaches are required in both basic and clinical research in order to finally eradicate this often devastating disease.
authors.affiliation: Department of Obstetrics and Gynaecology, Monash University, Monash Medical Center, Clayton, Victoria, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Wingfield
authors.forename: D L
authors.initials: DL
authors.lastname: Healy
mesh_terms: D003613:Danazol / Q000494:pharmacology / Q000627:therapeutic use; D004715:Endometriosis / Q000145:classification / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D004967:Estrogens / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005867:Gestrinone / Q000494:pharmacology / Q000627:therapeutic use; D017273:Goserelin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy; D010535:Laparoscopy; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology / Q000627:therapeutic use; D008593:Menopause; D017699:Pelvic Pain / Q000209:etiology; D011247:Pregnancy; D011256:Pregnancy Outcome; D012099:Reproductive Techniques; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D004967:Estrogens; D017273:Goserelin; D005867:Gestrinone; D017258:Medroxyprogesterone Acetate; D003613:Danazol